Clinical Trials
9 trialsNCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00262951 2017-12-28
Chemoradiation in Locally Advanced Pancreatic Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00613509 2016-04-14
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Sanofi
Phase 2 Terminated
NCT00098618 2013-07-02
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00015912 2013-01-25
Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00485563 2012-03-08
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Endocyte
Phase 2 Terminated
NCT00561912 2011-12-26
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00176527 2009-12-11
Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Rutgers, The State University of New Jersey
Phase 2 Terminated